Telo Genomics Corp. (TDSGF)

[dkelleyy]

GAMEPLAN per Feb 28, 2023 Filing (SEDAR MD&A)

March 2023 = Mayo SMM results have been submitted to the American Society of Clinical Oncology (ASCO) for presentation.
June 2023 = ISO 15189 approval that allows Telo to issue laboratory developed tests ("LDT") commercially.
June 2-6, 2023 = Telo at ASCO booth IH18.
June 2023 = Mayo SMM results to be submitted/published to a op-tier hematology journal (Probably the Blood Journal).
July 2023 = Launch of TeloView-MM laboratory developed tests ("LDT").
September 2023 = Anticipated Mayo results for testing to Predict Patient Resistance to Treatment.